{
    "clinical_study": {
        "@rank": "77340", 
        "arm_group": [
            {
                "arm_group_label": "Axillary Hyperhidrosis", 
                "description": "Patients with Axillary Hyperhidrosis who are treated with BOTOX\u00ae (botulinum toxin Type A) as prescribed according to standard of care in clinical practice."
            }, 
            {
                "arm_group_label": "Focal Spasticity", 
                "description": "Patients with Focal Spasticity who are treated with BOTOX\u00ae (botulinum toxin Type A) as prescribed according to standard of care in clinical practice."
            }, 
            {
                "arm_group_label": "Glabellar Lines", 
                "description": "Patients with moderate or severe Glabellar Lines who are treated with BOTOX\u00ae (botulinum toxin Type A) as prescribed according to standard of care in clinical practice."
            }
        ], 
        "brief_summary": {
            "textblock": "This post marketing surveillance study in Korea will evaluate the safety and efficacy of\n      BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of\n      care for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar\n      lines in clinical practice."
        }, 
        "brief_title": "Safety and Efficacy of BOTOX\u00ae (Botulinum Toxin Type A) in Korea", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hyperhidrosis", 
            "Muscle Spasticity", 
            "Glabellar Lines"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperhidrosis", 
                "Muscle Spasticity"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients treated with BOTOX\u00ae (botulinum toxin Type A) as prescribed according to\n             standard of care in clinical practice for primary axillary hyperhidrosis, focal\n             spasticity or moderate to severe glabellar lines.\n\n        Exclusion Criteria:\n\n          -  None."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients treated with BOTOX\u00ae (botulinum toxin Type A) as prescribed according to standard\n        of care in clinical practice."
            }
        }, 
        "enrollment": {
            "#text": "727", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02043145", 
            "org_study_id": "EPI-MULT-100"
        }, 
        "intervention": {
            "arm_group_label": [
                "Axillary Hyperhidrosis", 
                "Focal Spasticity", 
                "Glabellar Lines"
            ], 
            "description": "Botulinum toxin Type A (BOTOX\u00ae) as prescribed according to standard of care in clinical practice.", 
            "intervention_name": "botulinum toxin Type A", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "3", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Patients with Adverse Events and Serious Adverse Drug Reactions (SADRs)", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Hyperhidrosis Disease Severity Scale (HDSS) using a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, Post-dose (Up to 4 Years)"
            }, 
            {
                "measure": "Modified Ashworth Scale (MAS) using a 6-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, Post-dose (Up to 4 Years)"
            }, 
            {
                "measure": "Investigator Assessment of Glabellar Line Severity using a 4-point scale", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, Post-dose (Up to 4 Years)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02043145"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2008", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}